Moderna and CEPI expand alliance with $50M for new ebola vaccine
Moderna (NASDAQ:MRNA) has expanded its strategic collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate the development of an experimental vaccine targeting the Bundibugyo ebolavirus strain, an aggressive cause of Ebola virus disease for which there are currently no approved or licensed immunizations.










